Peptide Laws Outside the U.S.: Prescription-Only in Australia and New Zealand, Claims-Based in the UK, Raids in Malaysia and Thailand

In the space of six days, four countries made peptide news. On October 28, 2026, a coroner in Victoria, Australia, found that an injection of CJC-1295 and ipamorelin triggered the allergic reaction that killed actor Richard Norton. On November 1, customs officers at Bangkok's Suvarnabhumi Airport reported seizing 8,900 unregistered weight-loss pens from one passenger's suitcases. On November 2, Malaysia's health minister told Parliament about 12 raids on sellers of retatrutide, an obesity drug still in trials. The same day, pharmacists in Wellington said people injecting peptides were adding to a shortage of insulin syringes.

The products are much the same everywhere: BPC-157, TB-500, CJC-1295, and weight-loss drugs such as retatrutide and tirzepatide, usually bought online rather than from a pharmacy. The laws that apply to them are not. Australia and New Zealand treat many of these peptides as prescription-only medicines, so a buyer without a prescription can be breaking the law. The UK regulator mostly acts when a seller makes health claims or fakes a licensed medicine. Malaysia and Thailand have focused on unregistered weight-loss injections, through raids, airport seizures, and new prescription rules.

This guide covers each country's rules and recent enforcement, how that compares with the new U.S. compounding policy, and what travelers and online buyers risk. It is not legal advice. For U.S. rules, see Peptide Legality in 2026. For the Norton case and the evidence on CJC-1295 and ipamorelin, see the coroner finding explained.

The table simplifies. Each country's rules depend on the exact product, how it is labeled, and what the seller claims, and the sections below explain the details. The main split is between the first two rows and the rest. In Australia and New Zealand the substance itself is controlled. In the UK, Malaysia, and Thailand, the public statements we found center on unlicensed sellers and unregistered weight-loss drugs.

Australia's medicines regulator, the Therapeutic Goods Administration (TGA), told the Norton coroner in a September 2026 statement that CJC-1295, ipamorelin, BPC-157, thymosin beta-4, TB-500, "and many other peptides" are prescription-only medicines in Schedule 4 of the national Poisons Standard. None of them is on the Australian Register of Therapeutic Goods (ARTG), the list of approved medicines, so all are "unapproved." Doctors can still obtain unapproved products for a patient through special pathways, such as the Authorised Prescriber Scheme and the Personal Importation Scheme.

Because these peptides are prescription-only, having them without a prescription can be an offence under state law. In New South Wales, criminal lawyer Zoe Whetham told the Law Society Journal that the maximum penalty for possessing a prescribed restricted substance without a valid prescription is a fine of $2,200 and/or six months in prison. She said importing them from overseas without authorization can bring Commonwealth charges carrying up to five years in prison. Penalties vary by state and by case.

The TGA issued a safety advisory on unapproved peptides on April 13, 2026, listing reports of severe allergic reactions treated with adrenaline, whole-body inflammation needing hospital care, and poor product quality. On June 10, it made unapproved peptides a formal compliance priority, saying it could respond with infringement notices, product seizures, import interventions, and civil or criminal penalties. In July, TGA head Anthony Lawler said he had written to social media and e-commerce companies about peptide ads, and the TGA warned that influencers who promote these products can be held responsible for unlawful advertising even if they sell nothing.

Border enforcement has followed. The Australian Border Force (ABF) and the TGA said a joint operation that began after 640 vials were intercepted in August 2025 led to warrants in Melbourne on March 26, 2026. Officers seized more than 10,000 vials and 600 tablets, the agencies put the operation's seizures of steroids and peptide products at over $2 million in street value, and three people were charged with importing performance and image enhancing drugs.

NSW Health reported in October 2026 that 1,180 people went to emergency departments in the state after taking unapproved peptides between July 2025 and September 2026. Monthly visits rose from 5 to almost 220. Then, on October 28, Coroner David Ryan found that Norton's death followed an injection of a CJC-1295 and ipamorelin blend that his doctor said came from a licensed compounding pharmacy in Queensland. Ryan wrote that he was not satisfied these peptides belong in Schedule 4. He recommended that the TGA consider Schedule 10, the category for substances "of such danger to health as to warrant prohibition of supply and use," with exceptions for clinical trials and research. A recommendation is not a decision, and we found no TGA announcement of a change as of November 2.

In a consumer advisory published May 21, 2026, New Zealand's medicines regulator, Medsafe, said that under the Medicines Act 1981, "many peptide products and SARMs are prescription medicines," and that it is unlawful to "import, supply, possess or procure prescription medicines unless this is authorised." It named products commonly sold online, including BPC-157, CJC-1295, GHRP-6, ipamorelin, kisspeptin, KLOW, melanotan II, retatrutide, selank, semax, TB-500, and thymosin. Medsafe said a "for research purposes only" label "has no legal effect" and that it has approved no clinical trials of these products in New Zealand.

That is a change from a year earlier. In July 2025, RNZ reported that Medsafe could not seize peptides at the border if they were not classed as prescription medicines. Instead, it released them to buyers with a "high-risk medicine letter." In a submission to the Medicines Classification Committee, Medsafe asked for whole groups of peptides to be classified as prescription medicines, so that new versions would also be covered. Its May 2026 advisory says it continues to seize these products.

Medsafe's import rules allow up to three months' supply of a prescription medicine for a person's own use or their immediate family's, if they have a "reasonable excuse." For medicines sent by mail, Medsafe defines that as an original letter or prescription from a New Zealand prescriber that matches the product's name, strength, quantity, and form. Travelers carrying prescription medicines must declare them on the arrival card, keep them in their original containers, and carry a copy of the prescription or a doctor's letter. New Zealand Customs told RNZ that it refers suspected unapproved peptides to Medsafe.

New Zealand has also accepted that many people inject anyway. Health New Zealand has handed out more than 2,000 free peptide injecting kits since mid-September through needle exchanges and about 190 pharmacies, 1News reported on November 2. The agency said the kits do not mean it endorses unapproved peptides. Lesley McTurk, who heads a trust that runs needle exchanges across much of the North Island, told RNZ that peptide users now make up about 40% of its clients, where people injecting psychoactive drugs used to make up 85% to 90%. Wellington pharmacist Kelvin Lim told 1News that requests for insulin syringes from people injecting peptides had risen sharply and were adding to shortages for patients who need them.

In the UK, whether a peptide counts as a medicine depends largely on how it is sold. Lynda Scammell, head of borderlines at the Medicines and Healthcare products Regulatory Agency (MHRA), told STV News in March 2026 that the agency disregards "research purposes" labels "if it is clear that such claims are being used as an attempt to avoid medicines regulations." She also said, "Many peptides are sold for body-building purposes and in the absence of medicinal claims, these would not be considered medicines."

In April 2026, the MHRA told The Guardian that clinics offering peptide injections with medicinal claims are selling medicines regulated under the Human Medicines Regulations 2012, and that it would act against clinics breaking the law. The Guardian found clinic websites claiming that BPC-157 "aids in tissue repair" and thymosin alpha "boosts immune function," and the MHRA confirmed that such claims were not permitted. One clinic told the paper it charged £350 a month for one peptide and £450 for two.

The MHRA's biggest actions have targeted fake weight-loss pens. On October 14, 2026, its Criminal Enforcement Unit and West Midlands Police seized more than 12,000 fake retatrutide and tirzepatide pens, plus packaging for about 30,000 more, from an industrial unit in Birmingham. The MHRA valued the haul at about £2 million. It listed earlier raids: about 12,000 doses and two arrests at a country estate in May 2026, about 2,000 doses in February 2026, and in October 2025 the first illegal weight-loss drug factory found in the UK, with 5,000 pens. The agency said retatrutide is not authorized in the UK and that products sold as retatrutide outside legitimate clinical trials are "being supplied illegally."

The MHRA statements we found focus on sellers and clinics. We did not find an MHRA statement on whether a person who buys a peptide for their own use, without health claims attached, commits an offence. The National Pharmacy Association has called for an urgent review of "research only" sales, STV reported.

Malaysia's Health Ministry told The Star in June 2026 that retatrutide is not registered with the country's Drug Control Authority and cannot be imported, marketed, sold, or supplied. Under the Control of Drugs and Cosmetics Regulations 1984, every pharmaceutical product must be registered before it can be imported or sold, unless the law exempts it. The ministry said injectable weight-loss products are Group B poisons under the Poisons Act 1952, so even registered ones can be supplied only by a doctor, or by a pharmacist with a prescription.

The ministry has cited two sets of penalties. In June, it said individuals convicted of illegal sale, supply, or advertising face a fine of up to RM25,000, up to three years in prison, or both for a first offence, and companies up to RM50,000. In August, it said selling unregistered drugs under the Sale of Drugs Act 1952 carries fines of up to RM50,000 for a first offence and RM100,000 after that.

The ministry reported about 30 raids on illegal weight-loss product sellers from January to June 2026, with seizures worth RM477,142, and the removal of 209 online ads, including for retatrutide. The Star found "Reta Pens" sold online for RM250 to RM788. On November 2, Health Minister Dzulkefly Ahmad told Parliament that the ministry's Pharmacy Enforcement Division carried out 12 raids targeting retatrutide from 2025 to September 2026 and seized 697 units worth about RM341,000. Seven other actions seized 62 units of Ozempic and semaglutide worth RM64,170.

The minister also said patients who need GLP-1 treatment can apply through the ministry's special drug approval process, and that 240 treatment applications were approved from January to September 2026 at a cost of RM2.56 million. The Malaysian statements we found deal with weight-loss injections. We did not find official Malaysian statements on BPC-157 or other recovery peptides.

Thailand's Public Health Ministry issued Notification on Specially Controlled Drugs No. 58, which announced in March 2026, places injectable GLP-1 medicines such as semaglutide and liraglutide in the "specially controlled" category. From September 15, 2026, The Nation reported, pharmacies may sell them only with a doctor's prescription and must have a pharmacist dispense them. The Thai Food and Drug Administration (FDA) said it is also tracking GLP-1 pens from import to dispensing with a Track & Trace system, and that illegal drug advertising carries a fine of up to 100,000 baht.

On September 11, 2026, the Thai FDA and Bangkok police said they had seized unregistered peptide injection products and equipment worth more than 52 million baht from a house in Nonthaburi. The products were sold online for weight loss under the name "Haus of peptide." Police began investigating after a parent complained that their daughter had injected one. Investigators said the operation shipped about 100 boxes a day at 2,900 baht each. Authorities cited two offences under the Drug Act 1967: selling modern medicines without a license, punishable by up to five years in prison and a 10,000 baht fine, and selling unregistered medicines, punishable by up to three years and a 5,000 baht fine.

Airports are a second front. On October 31, customs officers at Suvarnabhumi Airport found 8,900 GLP-1 pens worth more than 5.34 million baht in two suitcases belonging to a passenger arriving from Bangladesh, the Thaiger reported from a Customs Department post. An officer said the pens were not registered with the Thai FDA, and the department said bringing them in broke the Customs Act and the Drug Act. In May, customs seized 137 packs of tirzepatide from another passenger on the same route.

The U.S. moved in a different direction the same week. On October 28, 2026, the Department of Health and Human Services said it would not take enforcement action against licensed pharmacies and doctors that compound six peptides, including BPC-157 and TB-500, for patients with a prescription. The policy does not make the peptides FDA-approved and can be withdrawn. Our guide to the HHS policy covers its conditions, and public comments are open until November 13.

Australia already allows doctors to prescribe and pharmacies to compound some unapproved peptides, and Norton's blend came from a licensed compounding pharmacy. The Victorian coroner's response was to ask whether that access should be narrowed. Pharmacy compounding does not settle whether these peptides are safe or effective, in either country.

On one point the countries agree. Regulators in the U.S., New Zealand, and the UK have all said that a "research use only" label does not protect a product that is clearly meant for people. Our explainer on what the research-use label means in the U.S. covers the FDA's side.

This section describes the rules regulators have published. It does not cover how to avoid them, and the safest step is to check with the regulator in the country you are entering before you buy or travel.

• A U.S. prescription does not make a product legal everywhere. In Australia, importing a prescription-only peptide under the Personal Importation Scheme requires a valid Australian prescription, a supply of no more than three months at the maximum dose, and no more than 15 months' supply in any 12 months, according to the Law Society Journal's summary of the regulations. New Zealand requires a New Zealand prescriber's letter or prescription for medicines sent by mail.
• Unlabeled vials will not be released. The TGA has said products identified only by codes, or that do not state the active ingredient and dose, cannot be assessed under the Personal Importation Scheme. Medsafe has said "research purposes only" wording has no legal effect.
• Declare medicines when you arrive. New Zealand requires travelers to declare prescription medicines on the arrival card. Medsafe's advice is: "If in doubt, declare it."
• A seized order is lost money. Shipments intercepted at the border can be destroyed, The Medical Republic noted in covering the TGA's July warning.
• Buying from a seller can still involve you in a crime. In Australia and New Zealand, the law on possessing prescription medicines applies to buyers, not only sellers. Malaysia bans the import of retatrutide outright.
• Retatrutide is not approved anywhere. Medsafe and the MHRA have said that retatrutide sold to the public comes from illegal sources, and Malaysia's Health Ministry says no regulator has approved it. See what lab tests found in online retatrutide.

If you have injected an unapproved product and feel unwell, get medical care and tell the clinician what you used. Flushing that spreads, chest tightness, wheezing, or throat swelling can be signs of anaphylaxis and need emergency care.